SPAQ

S Kant Healthcare

Product category
  • Sulfadoxine-pyrimethamine + amodiaquine in child-friendly dispersible formulation

  • Chemoprevention

Therapeutic indication
  • Seasonal Malaria Chemoprevention for children 3 to 59 months in eligible region
Dosing
  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months 

Efficacy
  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Average cost of intervention (SMC) to protect a child: US$ 3.40 per year (drug costs + delivery)
Challenges
  • Drug distribution to healthy subjects mainly via door-to-door campaigns
Status
  • ERP approved for one year until Feb 2020
  • Registered in 5 countries; ongoing in 5 other countries
  • Added on The Global Fund quality approved medicines list for procurement
Next milestone
  • First distributions in countries expected in 2019
  • WHO prequalification
MMV Project Director
  • Dr AndrĂ©-Marie Tchouatieu